Original Article
RASSF7 expression and its regulatory roles on apoptosis in human intervertebral disc degeneration

Zhi-Heng Liu[1*], Jun-Li Huo[2*], Zhi-Gang Wu[3*], Zhen Sun[4*], Feng Bai[1], Dino Samartzis[5], Benjamin Gantenbein[6], Shao-Di Fan[1], Hai-Qiang Wang[4]

[1]Department of Orthopaedics, Xi'an Air Force Hospital, PLA, 172 Youyi Eastern Road, Xi'an, P. R. China; Departments of [2]Neurosurgery, [4]Orthopaedics, Xijing Hospital, Fourth Military Medical University, 127 Changle Western Road, Xi'an, P. R. China; [3]Department of Orthopaedics, Lanzhou General Hospital of Lanzhou Military Region, PLA, Lanzhou, P. R. China; [5]Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong, SAR China; [6]Institute for Surgical Technology and Biomechanics, Tissue and Organ Mechanobiology, University of Bern, Bern, Switzerland. *Equal contributors.

Abstract: Apoptosis plays an important role in intervertebral disc degeneration (IDD). Overwhelming evidence indicates that RASSF7 is essential for cell growth and apoptosis. Recently, it has been noted that the JNK signaling can be negatively regulated by suppressing phosphorylated-MKK7 activation during pro-apoptosis. We aimed to investigate the RASSF7 expression level in human degenerative nucleus pulposus (NP) cells and non-degenerative NP cells and the link between RASSF7-JNK with NP cells apoptosis. We harvested NP tissues from 20 IDD patients as disease group and 8 cadaveric donors as normal controls. We detected RASSF7 expression by Real-time-PCR and western blotting. Consequently, we found that the expression of RASSF7 was higher in non-degenerative group than in degenerative group (P<0.05). Overexpression of RASSF7 in degenerative NP cells led to decreased apoptosis rate than that in scramble group (P<0.05). Collectively, our findings suggest that RASSF7 plays an important role in human IDD and RASSF7 might be potentially developed as a curative agent.

Keywords: Intervertebral disc degeneration, apoptosis, RASSF7, nucleus pulposus, JNK

Introduction

As the most disabling condition globally, low back pain (LBP) is one of the biggest problems for public health systems in the world [1]. However, many factors have been identified as possible causes of LBP [2-5], one of which is intervertebral disc degeneration (IDD) [6]. IDD occurs frequently in adults and is tightly linked with low back pain and sciatica [7-11], which are the most common diseases resulting in morbidity with overwhelming socioeconomic consequences [1, 12-14]. Hitherto, the underlying machinery of IDD has been largely unknown. We have noted that Fas-mediated apoptosis in human IDD can be promoted by the down regulation of miR-155 [15-17]. Furthermore, we have addressed the expression profiles of long noncoding RNAs and mRNAs of human IDD, in particular the mRNAs pertaining to apoptosis

[18]. Amongst the deregulated apoptosis-pertinent mRNAs, RASSF7 (NM_001143993) down-regulated up to 70 fold in IDD (P=0.0000141).

RASSF comprises a conserved motif named the RalGDS/AF6-type Ras association domain. RASSF7 is a newly defined RASSF member. Initially, RASSF7 was noted as HRAS cluster 1 on human chromosome 11p15.

In the past decade, apoptosis in IDD has ever become a research focus [13, 19]. Accumulating evidence suggests that apoptosis plays an essential role in pathogenesis of IDD in terms of *in vitro*, *in vivo*, studies [15, 20-22]. As for the apoptosis pathways, c-Jun N-terminal kinase (JNK) enzymes are important modulators of apoptosis in stress-activated signaling [23-27].

It is well established that Ras-association domain family proteins are involved in the regula-

Table 1. Demographic data of cadaveric donors and patients

Nucleus pulposus tissues	Age	Gender	Level	Degree*
Normal control (cadaveric donors)				
1	44	M	L4/5	I
2	38	M	L4/5	I
3	37	F	L4/5	I
4	45	M	L4/5	I
5	47	M	L4/5	I
6	39	F	L4/5	I
7	45	M	L4/5	I
8	39	M	L4/5	I
IDD Group (IDD patients)				
9	47	F	L4/5	IV
10	52	M	L4/5	IV
11	43	F	L4/5	V
12	36	F	L4/5	IV
13	42	M	L4/5	V
14	50	F	L5/S1	IV
15	45	F	L5/S1	IV
16	41	M	L4/5	IV
17	38	M	L4/5	IV
18	35	F	L5/S1	V
19	39	M	L4/5	IV
20	42	F	L5/S1	IV
21	52	M	L4/5	IV
22	42	M	L4/5	IV
23	46	M	L4/5	IV
24	38	F	L4/5	IV
25	49	F	L4/5	IV
26	36	M	L5/S1	IV
27	43	F	L4/5	IV
28	51	M	L4/5	IV

*Pfirrmann's grading system.

tion of JNK pathway [28]. The vertebrate RASSF consist of the classical RASSF members (RASSF1-6) and the newly defined N-terminal (NT) RASSF members (RASSF7-10) [29]. As the most investigated N-terminal RASSF protein, RASSF7 negatively modulates pro-apoptotic JNK signaling by suppressing phosphorylated-MKK7 activation [25].

However, there have been no studies reporting RASSF7 and its attendant roles in human IDD until now. Therefore, our research was aimed to investigate the role of RASSF7 in human NP cells and its putative roles in IDD.

Materials and methods

Sample collection

The Ethics Review Board of Xijing hospital, Xi'an, P. R. China (No. 20090611-3, No. 20111103-7) approved the study. As well, we signed informed consents with each patient and cadaveric donors' relatives. NP tissues from IDD patients were collected as degenerative group during discectomy [n=20; mean age: 43.4, SD: ±5.4; (range 35-52)] and normal cadaveric donors as control group [n=8; mean age: 41.8, SD: ±3.6; (range 37-47)] as we previously reported (**Table 1**). All the samples from patients with IDD were strictly selected to eliminate sequestration type of disc herniation. IDD degrees were classified by 3 experienced clinical observers who were blinded to the groups by Pfirrmann's MRI grading system [30]. We carefully dissected all samples under magnification and thereafter managed them in terms of specific conditions.

NP cell cultures

Following cautiously washed, redundant tissues including annulus fibrosus from outside of NP and cartilaginous endplate were detached. The rest of NP tissues underwent digestion for 40 min in PBS with 0.25% pronase at 37°C (Gibco-BRL, Carlsbad, CA, USA). Subsequently, further digestion was performed in PBS with 0.025% collagenase type II (Invitrogen) for 4 h. Following washed triple times with PBS, the digest was filtered via a nylon mesh with pore-size of 45-μm. Cells were cultured for three weeks in DMEM/F12-based culture medium, consisting of 15% fetal bovine serum (FBS; Gibco-BRL) and 1% penicillin/streptomycin (Invitrogen) in a 5% CO_2 incubator. The culture medium was renewed twice a week. NP cells with passage 1 or 2 were adapted for further studies.

RNA isolation and qRT-PCR

NP tissues were harvested from cadavers and IDD patients. We extracted total RNA by Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was acquired by using High-Capacity cDNA

Figure 1. RASSF7 expression in degenerative NP cells. A. qRT-PCR analysis of RASSF7 expression. B. Western blotting detection of RASSF7 expression.

Archive Kit (ABI, Foster City, CA, USA). Primers for human RASSF7 and human GAPDH were purchased from Invitrogen (Invitrogen, NY, USA). NanoDrop (NanoDrop, Wilmington, DE, USA) was used to detect the concentrations of RNA. The RASSF7 expression levels were normalized to GAPDH mRNA controls. All RT reactions, including GAPDH controls, were run in triplicate in a GeneAmp PCR 9700 Thermocycler (ABI). The relative amounts of RASSF7 mRNA were calculated using the comparative Ct ($2^{-\Delta\Delta Ct}$) method. The primers used were as follows: RASSF7 forward: 5'-CAAAGGCCACGACT-GCCTGTT-3', reverse: 5'-GGCACAGGCAACATGA-CAGAGA-3'; GAPDH forward: 5'-GCACCGTCAA-GGCTGAGAAC-3', reverse: 5'-TGGTGAAGACGC-CAGTGGA-3'.

Western blotting analysis

RASSF7 expression was detected by western blotting analysis in IDD group and control group. Following solubilizing cells in 2X SDS buffer, electrophoresized using 10% gel, proteins were transferred to PVDF membrane. The membranes were incubated for 1 h at room temperature with rabbit-anti-human antibody for RASSF7 (Abcam, USA). Mouse antibody to β-actin (Sigma, Saint Louis, USA) was used as control. IRDye 800 anti-rabbit or anti-mouse IgG antibody (LI-COR Biosciences, Nebraska, USA) was used to label antibodies. LI-COR Odyssey Imaging System was used to analyze expression levels.

Up-regulation of RASSF7 with lentiviral vector

We purchased lentiviral vectors encoding RA-SSF7 with green fluorescent protein (GFP) labeling Genechem (Genechem, Shanghai, P. R. China). We used a scrambled sequence as con-

trol. *In vitro* cultured NP cells were inoculated (Density: 1.5×10^5 cells/well) into a 24-well plate. The final volume of complete medium was 250 µL. The multiplicity of infection (MOI) for viral solutions was 10. Following incubation for 10 h and 96 h of recovery, culture flasks were investigated under fluorescent microscopy to confirm viral transfection.

Flow cytometry (FCM) analysis

FCM of NP cells 1 d following transfection was performed with APC Annexin V/7-AAD (BD Biosciences, San Diego, CA, USA) staining using standard protocol. Triple repeats were performed for each experiment.

Statistical analysis

For comparison between parameters of 2 groups, student's t-test was used. A *P* value less than 0.05 was considered as statistically significant. The SPSS 12.0 statistical package (SPSS, Chicago, IL, USA) was used for statistical analyses.

Results

Different levels of RASSF7 expression in human degenerative and normal NP cells

The mRNA expression level of RASSF7 in IDD was considerably lower than that of normal control (**Figure 1A**). Furthermore, the intensity of RASSF7 in IDD group was lower than that in control as a result of western blotting (**Figure 1B**). Quantitatively, the average RASSF7 percentage in IDD was mean: 0.243, SD: 0.03; whereas the average RASSF7 ratio in control was mean: 0.64, SD: 0.07 (*P*<0.05). Taken together, these results indicate the existence of

Figure 2. Apoptosis rate detection after up-regulated RASSF7 in IDD NP cells. A. Brightfield (left) and fluorescent (right) microscopy of degenerative NP cells tranfected with lentivirus labeled with green fluorescent protein. Scale bars =20 μm. B. Diagram of APC AnnexinV-/7-AADFCM of transfected NP cells. The graphs stand for typicalresults of apoptosis; values symbolize the average values of three experiments. C. Comparison of apoptotic cells between up-regulated RASSF7 groups and control goup (*$P<0.05$).

RASSF7 in human NP. Moreover, RASSF7 was down-regulated in human degenerative NP at both the mRNA and the protein level.

Up-regulation of RASSF7 in degenerated NP cells can lead to decreased apoptosis

The lentiviral transfection with RASSF7 led to GFP expression at high level (**Figure 2A**). FCM resulted in the apoptosis of transfected NP cells (**Figure 2B**). The apoptotic rate in up-regulated RASSF7 group was mean: 0.197, SD: 0.038. Approximately mean 0.50, SD: 0.114 apoptosis rate was detected in control group (**Figure 2C**). Our study found that up-regulated RASSF7 resulted in decreased apoptotic rate of degenerative NP cells ($P<0.05$).

Discussion

This study presents the first line of evidence unraveling the function of RASSF7 in human IDD. We detected the expression level of RASSF7 in human NP tissues and clarified its attendant roles in IDD for the first time.

Importantly, *in vitro* modulation of RASSF7 expression in human NP cells can influence apoptosis, which might provide novel insights on the etiology of human IDD in terms of apoptosis machinery. IDD is a complicated pathological process, including various degenerative events such as cell death, miRNAs, gene polymorphisms and unbalanced immune privilege.

There are a number of lines of evidence indicating that apoptosis plays an essential role in pathogenesis of IDD [13, 19, 20]. Recently, researchers found that JNK enzymes, as the modulators of apoptosis, can be regulated by RASSF7 repressing the activity of phosphorylated-MKK7 to affect cell apoptosis [25]. RASSF7, previously known asHRC1 (HRAS1 cluster 1) and C11orf13, is a component of the N-terminal RASSF family [31]. Previous studies have shown that RASSF7 has putative roles in the regulation of cell growth and apoptosis. According to related studies, RASSF7 protein has been noted in various human cell lines [28, 32], and was found to elevate levels in the

hypoxic tissue of epithelial tumors [28, 33, 34]. As the intervertebral disc is the most avascular structure, NP tissue is in hypoxic conditions.

JNK enzymes are important modulators of apoptosis. JNK activation promotes the stability and transcriptional vitality of JNK substrates, subsequently mediating cell apoptosis via the MAPKKKs-MKK4/MKK7-JNK activation pathway. Takahashi et al. found that exclusive RASSF7 inhibition leads to anti-apoptotic regulation and increases cell protection from inappropriate JNK activation [25, 35]. Recent studies delineate that JNK activation in later phase (1-6 h) mediates pro-apoptotic signaling [36, 37]. NP cells play an essential role in the resistance against mechanical loadings by the synthesis of ECM to maintain the stability of intervertebral discs. Cell loss due to apoptosis might lead to IDD pathological process. Based on the high expression level of RASSF7 in non-degenerative NP cells, we propose that RASSF7 modulates the apoptosis of NP cells though RASSF7-MKK7-JNK pathway.

We over-expressed RASSF7 in degenerative NP cells using lentiviral vectors. The apoptotic rate of degenerative NP cells with upregulated RASSF7 is significant lower than that in scramble group. It should be stressed that the mechanisms of RASSF7-JNK links in human NP were clarified, which might cast light on the expression of RASSF7 in IDD. Previously, the function of RASSF7 especially in cell death has been noted. RASSF7 knockdown in neural tube cells presumably contributes to nuclear fragmentation and cell death [28, 38]. Takahashi et al. suggested that RASSF7 negatively regulates pro-apoptotic JNK signaling. In supplement with these studies, our findings showed that the apoptotic rate of degenerative NP cells was decreased after up-regulation of RASSF7, which might be due to apoptosis inhibition through RASSF7-JNK signaling.

Collectively, our study suggests that RASSF7 plays an important role in human IDD and that RASSF7 could be developed as a curative agent.

Acknowledgements

Disclosure of conflict of interest

None.

Address correspondence to: Hai-Qiang Wang, Department of Orthopaedics, Xijing Hospital, Fourth Military Medical University, 127 Changle Western Road, Xi'an 710032, P. R. China. Tel: +86 84775288; E-mail: hqwang@fmmu.edu.cn; Shao-Di Fan, Department of Orthopaedics, Xi'an Air Force Hospital, 172 Youyi Eastern Road, Xi'an 710054, P. R. China. Tel: +86 132 7921 3096; E-mail: fansd666@163.com

References

[1] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Ja-

cobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.

[2] Roffey DM, Wai EK, Bishop P, Kwon BK and Dagenais S. Causal assessment of occupational sitting and low back pain: results of a systematic review. Spine J 2010; 10: 252-261.

[3] Shiri R, Karppinen J, Leino-Arjas P, Solovieva S and Viikari-Juntura E. The association between obesity and low back pain: a meta-analysis. Am J Epidemiol 2010; 171: 135-154.

[4] Shiri R, Karppinen J, Leino-Arjas P, Solovieva S and Viikari-Juntura E. The association between smoking and low back pain: a meta-analysis. Am J Med 2010; 123: 87, e87-35.

[5] Wang H, Schiltenwolf M and Buchner M. The role of TNF-alpha in patients with chronic low back pain-a prospective comparative longitudinal study. Clin J Pain 2008; 24: 273-278.

[6] Le Maitre CL, Binch AL, Thorpe AA and Hughes SP. Degeneration of the intervertebral disc with new approaches for treating low back pain. J Neurosurg Sci 2015; 59: 47-61.

[7] Takatalo J, Karppinen J, Niinimaki J, Taimela S, Mutanen P, Sequeiros RB, Nayha S, Jarvelin MR, Kyllonen E and Tervonen O. Association of modic changes, Schmorl's nodes, spondylolytic defects, high-intensity zone lesions, disc herniations, and radial tears with low back symptom severity among young Finnish adults. Spine (Phila Pa 1976) 2012; 37: 1231-1239.

[8] Samartzis D, Karppinen J, Cheung JP and Lotz J. Disk degeneration and low back pain: are they fat-related conditions? Global Spine J 2013; 3: 133-144.

[9] Samartzis D, Karppinen J, Chan D, Luk KD and Cheung KM. The association of lumbar intervertebral disc degeneration on magnetic resonance imaging with body mass index in overweight and obese adults: a population-based study. Arthritis Rheum 2012; 64: 1488-1496.

[10] Samartzis D, Ito K and Wang JC. Disk degeneration and pain. Global Spine J 2013; 3: 125-126.

[11] Samartzis D and Cheung KM. Lumbar intervertebral disk degeneration. Orthop Clin North Am 2011; 42: xi-xii.

[12] Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E, Carrino J, Chou R, Cook K, DeLitto A, Goertz C, Khalsa P, Loeser J, Mackey S, Panagis J, Rainville J, Tosteson T, Turk D, Von Korff M and Weiner DK. Report of the NIH Task Force on Research Standards for Chronic Low Back Pain. Spine J 2014; 14: 1375-1391.

[13] Ding F, Shao ZW and Xiong LM. Cell death in intervertebral disc degeneration. Apoptosis 2013; 18: 777-785.

[14] Karppinen J, Shen FH, Luk KD, Andersson GB, Cheung KM and Samartzis D. Management of degenerative disk disease and chronic low back pain. Orthop Clin North Am 2011; 42: 513-528, viii.

[15] Wang HQ, Yu XD, Liu ZH, Cheng X, Samartzis D, Jia LT, Wu SX, Huang J, Chen J and Luo ZJ. Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degen-

eration by targeting FADD and caspase-3. J Pathol 2011; 225: 232-242.

[16] Wang HQ. Bring stem cell therapies to cure intervertebral disc degeneration to the forefront. Curr Stem Cell Res Ther 2015; 10: 284.

[17] Ma CJ, Liu X, Che L, Liu ZH, Samartzis D and Wang HQ. Stem Cell Therapies for Intervertebral Disc Degeneration: Immune Privilege Reinforcement by Fas/FasL Regulating Machinery. Curr Stem Cell Res Ther 2015; 10: 285-295.

[18] Wan ZY, Song F, Sun Z, Chen YF, Zhang WL, Samartzis D, Ma CJ, Che L, Liu X, Ali MA, Wang HQ and Luo ZJ. Aberrantly expressed long noncoding RNAs in human intervertebral disc degeneration: a microarray related study. Arthritis Res Ther 2014; 16: 465.

[19] Zhao CQ, Jiang LS and Dai LY. Programmed cell death in intervertebral disc degeneration. Apoptosis 2006; 11: 2079-2088.

[20] Han D, Ding Y, Liu SL, Wang G, Si IC, Wang X, Cui L and Huang D. Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 938-947.

[21] Liu ZH, Sun Z, Wang HQ, Ge J, Jiang TS, Chen YF, Ma Y, Wang C, Hu S, Samartzis D and Luo ZJ. FasL expression on human nucleus pulposus cells contributes to the immune privilege of intervertebral disc by interacting with immunocytes. Int J Med Sci 2013; 10: 1053-1060.

[22] Wang H, Liu H, Zheng ZM, Zhang KB, Wang TP, Sribastav SS, Liu WS and Liu T. Role of death receptor, mitochondrial and endoplasmic reticulum pathways in different stages of degenerative human lumbar disc. Apoptosis 2011; 16: 990-1003.

[23] Chen F. JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res 2012; 72: 379-386.

[24] Dhanasekaran DN and Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.

[25] Takahashi S, Ebihara A, Kajiho H, Kontani K, Nishina H and Katada T. RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the activity of phosphorylated-MKK7. Cell Death Differ 2011; 18: 645-655.

[26] Verma G and Datta M. The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death. J Cell Physiol 2012; 227: 1791-1795.

[27] Zhang L, Zhou M, Wang Y, Huang W, Qin G, Weintraub NL and Tang Y. miR-92a inhibits vascular smooth muscle cell apoptosis: role of the MKK4-JNK pathway. Apoptosis 2014; 19: 975-983.

[28] Recino A, Sherwood V, Flaxman A, Cooper WN, Latif F, Ward A and Chalmers AD. Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis. Biochem J 2010; 430: 207-213.

[29] Underhill-Day N, Hill V and Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011; 6: 284-292.

[30] Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J and Boos N. Magnetic resonance classification of lumbar intervertebral disc degeneration. Spine (Phila Pa 1976) 2001; 26: 1873-1878.

[31] Sherwood V, Recino A, Jeffries A, Ward A and Chalmers AD. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2010; 425: 303-311.

[32] Sherwood V, Manbodh R, Sheppard C and Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008; 19: 1772-1782.

[33] Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM and Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14: 1340-1348.

[34] Liang GP, Su YY, Chen J, Yang ZC, Liu YS and Luo XD. Analysis of the early adaptive response of endothelial cells to hypoxia via a long serial analysis of gene expression. Biochem Biophys Res Commun 2009; 384: 415-419.

[35] Wolfman JC, Palmby T, Der CJ and Wolfman A. Cellular N-Ras promotes cell survival by down-regulation of Jun N-terminal protein kinase and p38. Mol Cell Biol 2002; 22: 1589-1606.

[36] Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC and Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-613.

[37] Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM and Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 2006; 21: 701-710.

[38] Goshima G, Wollman R, Goodwin SS, Zhang N, Scholey JM, Vale RD and Stuurman N. Genes required for mitotic spindle assembly in Drosophila S2 cells. Science 2007; 316: 417-421.